[go: up one dir, main page]

MX2018013387A - Inhibidores de la arginasa y sus aplicaciones terapeuticas. - Google Patents

Inhibidores de la arginasa y sus aplicaciones terapeuticas.

Info

Publication number
MX2018013387A
MX2018013387A MX2018013387A MX2018013387A MX2018013387A MX 2018013387 A MX2018013387 A MX 2018013387A MX 2018013387 A MX2018013387 A MX 2018013387A MX 2018013387 A MX2018013387 A MX 2018013387A MX 2018013387 A MX2018013387 A MX 2018013387A
Authority
MX
Mexico
Prior art keywords
arginase
therapeutic applications
arginase inhibitors
compounds
activity
Prior art date
Application number
MX2018013387A
Other languages
English (en)
Other versions
MX378806B (es
Inventor
Golebiowski Adam
BOREK Bartlomiej
BLASZCZYK Roman
Nowicka Julita
BRZEZINSKA Joanna
GZIK Anna
Dziegielewski Marek
JEDRZEJCZAK Karol
Matyszewski Krzysztof
OLCZAK Jacek
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Publication of MX2018013387A publication Critical patent/MX2018013387A/es
Publication of MX378806B publication Critical patent/MX378806B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen compuestos terapeuticos de moleculas pequenas que son potentes inhibidores de la actividad de la arginasa 1 y arginasa 2. Tambien se describen composiciones farmaceuticas que comprenden los compuestos y metodos para usar los compuestos para tratar o prevenir una enfermedad o afeccion asociada con la actividad de la arginasa.
MX2018013387A 2016-05-04 2017-05-02 Inhibidores de la arginasa y sus aplicaciones terapéuticas. MX378806B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662331550P 2016-05-04 2016-05-04
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
US201762444669P 2017-01-10 2017-01-10
PCT/EP2017/060413 WO2017191130A2 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications

Publications (2)

Publication Number Publication Date
MX2018013387A true MX2018013387A (es) 2019-02-28
MX378806B MX378806B (es) 2025-03-11

Family

ID=60190450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013387A MX378806B (es) 2016-05-04 2017-05-02 Inhibidores de la arginasa y sus aplicaciones terapéuticas.

Country Status (24)

Country Link
US (3) US10391077B2 (es)
EP (1) EP3452485B1 (es)
JP (1) JP6971477B2 (es)
KR (1) KR102374788B1 (es)
CN (1) CN109415387B (es)
AU (1) AU2017259887B2 (es)
BR (1) BR112018072545B1 (es)
CA (1) CA3022482C (es)
CL (1) CL2018003132A1 (es)
CO (1) CO2018013077A2 (es)
DK (1) DK3452485T3 (es)
ES (1) ES2834065T3 (es)
HR (1) HRP20201821T1 (es)
HU (1) HUE052468T2 (es)
IL (1) IL262387B (es)
LT (1) LT3452485T (es)
MX (1) MX378806B (es)
PE (1) PE20181924A1 (es)
PH (1) PH12018501976A1 (es)
PL (2) PL417066A1 (es)
SA (1) SA518400356B1 (es)
SG (1) SG11201807974QA (es)
SI (1) SI3452485T1 (es)
WO (1) WO2017191130A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5909239B2 (ja) 2010-10-26 2016-04-26 マーズ インコーポレイテッド アルギナーゼ阻害剤としてのボロネート
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
CA3003271A1 (en) 2015-10-30 2017-05-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
NZ745681A (en) 2016-03-07 2022-05-27 Agrofresh Inc Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
HUE054272T2 (hu) 2016-12-22 2021-09-28 Calithera Biosciences Inc Összetételek és módszerek az argináz-tevékenység gátlásához
AU2019221896B2 (en) 2018-02-17 2022-03-24 Astrazeneca Ab Arginase inhibitors and methods of use thereof
SG11202008113RA (en) * 2018-03-05 2020-09-29 Arcus Biosciences Inc Arginase inhibitors
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
EP3774843B1 (en) * 2018-03-29 2022-05-25 Molecure SA Dipeptide piperidine derivatives
US11274111B2 (en) * 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
UY38476A (es) 2018-11-16 2020-06-30 Arcus Biosciences Inc Inhibidores de arg1 y/o arg2
EP3897622B1 (en) * 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
CN118286450A (zh) 2019-11-12 2024-07-05 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US20240336635A1 (en) 2023-04-06 2024-10-10 Molecure S.A. Process for the production of (1r,2s,5r)-1-amino-5-[2-(dihydroxyboranyl)ethyl]-2-[(dimethylamino)methyl]-cyclohexane-1-carboxylic acid

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016192A1 (en) 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
EP1604978A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals Trans pyrrolidinyl derivatives and their pharmaceutical uses
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
US20100056480A1 (en) 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
JP2012515799A (ja) 2009-01-26 2012-07-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア アルギナーゼ阻害剤および使用方法
US9040703B2 (en) 2010-04-22 2015-05-26 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
JP5909239B2 (ja) * 2010-10-26 2016-04-26 マーズ インコーポレイテッド アルギナーゼ阻害剤としてのボロネート
JP2014506253A (ja) 2010-12-31 2014-03-13 コリドー ファーマシューティカルズ インコーポレイテッド アルギナーゼ阻害剤およびその使用法
BR112014009415B1 (pt) 2011-10-19 2021-11-23 Mars, Incorporated Composição farmacêutica, composto inbidor de arginase e seus usos
MX355758B (es) * 2012-04-18 2018-04-27 Mars Inc Analogos constreñidos en el anillo como inhibidores de arginasa.
SI2872515T1 (sl) 2012-07-13 2016-10-28 Janssen Sciences Ireland Uc Makrociklični purini za zdravljanje virusnih infekcij
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201890113A1 (ru) 2015-06-23 2018-07-31 Калитера Байосайенсиз, Инк. Композиции и способы ингибирования активности аргиназы
CA3003271A1 (en) 2015-10-30 2017-05-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2017356942A1 (en) 2016-11-08 2019-05-23 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2019145453A1 (en) 2018-01-28 2019-08-01 Universite De Geneve Arginase suppression for cancer treatment

Also Published As

Publication number Publication date
JP2019518726A (ja) 2019-07-04
PL3452485T3 (pl) 2021-04-19
CA3022482C (en) 2024-06-11
SG11201807974QA (en) 2018-10-30
AU2017259887A1 (en) 2018-09-27
HRP20201821T1 (hr) 2021-04-16
ES2834065T3 (es) 2021-06-16
IL262387B (en) 2021-10-31
CA3022482A1 (en) 2017-11-09
DK3452485T3 (da) 2020-11-09
PL417066A1 (pl) 2017-11-06
JP6971477B2 (ja) 2021-11-24
PE20181924A1 (es) 2018-12-11
BR112018072545B1 (pt) 2022-08-23
AU2017259887B2 (en) 2022-03-17
CN109415387A (zh) 2019-03-01
US20170319536A1 (en) 2017-11-09
US10912755B2 (en) 2021-02-09
US20190365701A1 (en) 2019-12-05
WO2017191130A2 (en) 2017-11-09
US12053451B2 (en) 2024-08-06
WO2017191130A3 (en) 2017-12-14
EP3452485B1 (en) 2020-09-09
CL2018003132A1 (es) 2019-02-22
PH12018501976A1 (en) 2019-07-01
KR102374788B1 (ko) 2022-03-15
SA518400356B1 (ar) 2022-01-19
LT3452485T (lt) 2020-12-28
BR112018072545A2 (pt) 2019-06-25
IL262387A (en) 2018-12-31
CO2018013077A2 (es) 2019-04-30
US10391077B2 (en) 2019-08-27
SI3452485T1 (sl) 2021-01-29
KR20190015250A (ko) 2019-02-13
EP3452485A2 (en) 2019-03-13
HUE052468T2 (hu) 2021-04-28
NZ746211A (en) 2024-12-20
CN109415387B (zh) 2021-08-27
WO2017191130A4 (en) 2018-03-01
US20210260019A1 (en) 2021-08-26
MX378806B (es) 2025-03-11

Similar Documents

Publication Publication Date Title
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
CL2019000819A1 (es) Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
MX2021009673A (es) Moduladores de ror-gamma.
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
MX2017011018A (es) Inhibicion de la actividad de olig2.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX2019002259A (es) Inhibicion de la actividad de la olig2.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
CL2017002229A1 (es) Inhibidores de bace1.